Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

      Prescribing Information Link
      Summary of Product Characteristics Link

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson’s medicinal products have not given satisfactory results.1
       

      Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
       
      Prescribing Information Link
      Summary of Product Characteristics Link

      PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson’s medicinal products have not given satisfactory results.1

      Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.

      Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing information (PI), and Summary of Product Characteristics (SmPC) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.

      PRODUODOPA resources

      Hear about PRODUODOPA from leading experts, including the key clinical data, case studies, the Homecare Service and onboarding patients onto PRODUODOPA.

      The content on this page contains information about DUODOPA (levodopa/carbidopa intestinal gel). Please refer to the DUODOPA Prescribing Information for more information about this product.

      18 months on: Our centre's learnings

      Dr Amrit Samra, Consultant Neurologist, shares his insights into the use of Produodopa 18 months after it became available in the UK.

      This is a recording from a promotional meeting.

      Evolving our PD service: A centre's approach to patient maintenance in the community

      Amanda Hulejczuk, Consultant Parkinson's Nurse, discusses the Produodopa service within her centre and how this has evolved

      This is a recording from a promotional meeting.

      What can be achieved with less resources?

      Elisabete Marquez, Parkinson's Clinical Nurse Specialist, outlines the Produodopa service within her centre and how this has been optimised to initiate patients with minimum resources.

      This is a recording from a promotional meeting.

      Long-term patient management

      Professor Camille Carroll, Principal Investigator of the clinical trials investigating PRODUODOPA at University Hospitals Plymouth and Professor of Clinical Neuroscience at Newcastle University, describes her experience of following up patients who took part in Produodopa clinical trials.

      This is a recording from a promotional meeting.

      Protocols in Practice

      A panel of experts from the UK discuss the key challenges, processes and learnings around set-up and optimisation of a Parkinson’s disease service.

      This is a recording from a promotional meeting.

      Exploring the patient experience

      A panel of UK experts in Parkinson’s Disease from centres with established PRODUODOPA services explore considerations for patient management, initiation, and maintenance with PRODUODOPA, using patient case studies to share best practice and key learnings.

      This is a recording from a promotional meeting.

      Patient suitability and practical considerations for PRODUODOPA treatment

      Professor Camille Carroll, Principal Investigator of the clinical trials investigating PRODUODOPA at University Hospitals Plymouth and Professor of clinical neuroscience at Newcastle University, offers insight into identifying suitable patients for PRODUODOPA treatment and clinical practicalities of implementing the therapy.

      This is a recording from a promotional meeting.

      Initiating PRODUODOPA treatment: Centre-based case studies of onboarding experiences

      A panel discussion involving representatives from three of the first UK centres to employ PRODUODOPA in their services, who compare patient case studies and experiences, offering insight and advice to Parkinson’s Disease healthcare professionals.

      This is a recording from a promotional meeting.

      Diving into the data: Efficacy and safety of PRODUODOPA

      Professor K Ray Chaudhuri, Director of the Parkinson Foundation International Centre of Excellence at King’s College London, presents the efficacy and safety results from key PRODUODOPA clinical trials.

      This is a recording from a promotional meeting.

      Running a PRODUODOPA service: My centre’s experience

      Professor Stephen Mullin, Neurology Consultant and Movement Disorder Specialist at University Hospital of Plymouth NHS trust, describes the process by which the Trust implemented and scaled the PRODUODOPA service in the South-West Peninsula, and shares details on how discussions with stakeholders have shaped the service.

      This is a recording from a promotional meeting.

      This page will be updated regularly. Visit again at a later date for more resources.

      Please refer to the PRODUODOPA Summary of Product Characteristics (SmPC) for further information on adverse events, contraindications and special warnings and precautions for use.

      Contact Us

      References

      1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics.
      PRODUODOPA PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-PRODD-260244. Date of preparation: June 2026.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250400. Date of preparation December 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.